Ascendis Pharma A/S (ASND)
About Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $13.0B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $13.0B
- Shares outstanding
- 51.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 20, 2026
Ascendis Pharma A/S (ASND) Stock Price
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ascendis Pharma A/S.
Write a review
News about Ascendis Pharma A/S
News & sentiment via Polygon.io
Ascendis Pharma A/S: frequently asked questions
Is Ascendis Pharma A/S an American company?
Ascendis Pharma A/S is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Ascendis Pharma A/S publicly traded?
Yes — Ascendis Pharma A/S is a publicly traded company. Its stock trades under the ticker symbol ASND on the NASDAQ.
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S is an American Pharmaceuticals company in the Health & Beauty sector.
